Overview

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This study will investigate the effect of PF-04950615, a new investigational lipid lowering agent, on LDL-C and other lipids.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Bococizumab
Hydroxymethylglutaryl-CoA Reductase Inhibitors